Eli Lilly: Mounjaro And Zepbound Keep The Growth Story Alive
View original →Cite asCryptoQuant has tracked the directional calls on LLY by @allka-research on Seeking Alpha since Jun 2024: not yet scored on LLY (as of Nov 18, 2026).
3 LLY calls on record, a thin history.
Relative view by default: fewer than 30 LLY calls or days on record.
Sentiment timeline shows relative sentiment within this analyst's history. A perma-bull showing 8 bullish : 2 bearish in a bear market sets that as their baseline. If you notice any errors, claim @seekingalpha:allka-research to submit corrections.
Hover the chart to read the thesis of that period · click a day to pin it
Eli Lilly: Mounjaro And Zepbound Keep The Growth Story Alive
View original →BeOne Medicines: Brukinsa And Tevimbra Face A High Bar
View original →Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)
View original →Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs
Adding dividend yield and forward P/E, Pfizer offers one of the most appealing risk/reward profiles.
View original →I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)
Strong incretin sales, retatrutide data, high margins and upcoming catalysts justify upgrading Lilly to Buy.
View original →